Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alirocumab
4
×
biotech
boston blog main
life sciences
national blog main
new york blog main
new york top stories
regeneron pharmaceuticals
amgen
boston top stories
evolocumab
inclisiran
national top stories
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
fda
heart attack
indiana blog main
indiana top stories
medicines co.
national
new york
pcsk9
pcsk9 inhibitors
raleigh-durham blog main
raleigh-durham top stories
rna interference
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sanofi
seattle blog main
seattle top stories
stroke
texas blog main
What
drug
cholesterol
new
drugs
long
lowering
medco
medicines
wave
acquire
afternoon
agreed
alnylam
anticipated
awaited
based
billion
blueprint
brings
cash
company
compound
cost
cut
data
deal
details
evidence
expensive
faces
fda
financial
foe
healthcare
heart
hint
house
inhibitors
known
lasting
Language
unset
Current search:
alirocumab
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Trump Pledges Lower Drug Prices, But Blueprint Is Short on Details